Home Infusion Therapy Devices Market

Home Infusion Therapy Devices Market: Site-of-Care Economics, Subcutaneous Conversion, and Infection Liability

Home infusion exists because payers want to avoid a hospital bill, and the fastest-growing device in the category is the one that removes the pump, the line and the nurse visit altogether.

Lead Analyst

Alice Ballenger

Published

September 2026

Make Smarter Decisions with Customized Research Insights

Request a free sample report and evaluate market opportunities, growth trends, and competitive dynamics relevant to your business needs.

2025 MARKET VALUE$6.8BMarket Size 2025

2036 FORECAST VALUE$17.2BBase Case , 2026 to 2036

CAGR 2026 TO 20368.8 %Bull 10.0% / Bear 7.6%

INCREMENTAL OPPORTUNITY$9.8BNet 10- year value creation

EXPANSION MULTIPLE2.32x2036 value over 2026 base

Strategic Levers

M&A Pipeline

Regional Outlook

Country Rankings

Competitive Intelligence

Segmental Deep-dive

Call-Us : 91 93563 13602

Executive Snapshot and Market Trajectory

This is a reimbursement product wearing clinical clothing. Home infusion grew because delivering a therapy at home costs a payer far less than the same therapy in a hospital outpatient suite, and every commercial argument in the category traces back to that single comparison. Clinical preference barely enters it.

On-body wearable injectors compound at 13.2%, a full 1.50x the market rate, and they grow by dismantling infusion rather than extending it. Subcutaneous conversion of intravenous biologics removes the pump, the catheter and the nursing visit in one step. North America holds 32% of value because the United States built a home infusion provider network no other health system has attempted, on payer economics no other system needed.

Concentration is moderate at 51%, with Baxter International and ICU Medical leading a group whose revenue sits overwhelmingly in disposables rather than pumps. Elastomeric devices, the least sophisticated products in the category, are growing at 10.4% precisely because they carry no electronics to fail and need almost no training. Catheter-related bloodstream infection remains the outcome that decides whether a programme survives. A single cluster closes a programme outright. Savings never survive an infection cluster.

Market Definition

This market covers devices and single-use consumables used to deliver parenteral therapy in home and ambulatory settings, spanning ambulatory electronic infusion pumps, elastomeric disposable pumps, syringe infusion pumps, vascular access devices, infusion administration sets and needleless connectors, and on-body wearable injectors. Measurement is at manufacturer revenue attributable to home and ambulatory use. Hospital bedside infusion pumps, home infusion nursing and pharmacy services, the infused drugs themselves, enteral feeding systems, and dialysis equipment are excluded.

Base Year Value

$6.8B in 2025 (MMA Primary Research Dataset, August 2026)

Forecast Period

2026 to 2036, eleven discrete annual values

CAGR

8.8% base case. Bull 10.0%. Bear 7.6%.

Fastest Growth Segment

On-Body Wearable Injectors: 13.2% CAGR

Fastest Growth Country

India: 12.8% CAGR

Fastest Growth Region

South Asia and Pacific: 11.0% CAGR

Largest Region

North America: 32% of 2025 global value

Market Leaders

Baxter International, ICU Medical, B. Braun, Becton Dickinson, and Fresenius Kabi. Source: MMA Primary Research Dataset, July 2026.

Primary Survey

n=3,800 procurement and R&D decision-makers, Q4 2025, six countries

Methodology

Demand-side build-up, cross-validated against public data, 47 expert interviews

Home Infusion Therapy Devices Market Forecast Scenarios

home-infusion-therapy-devices-market-size-forecast-scenario-1787303476113

Growth ran at roughly 7.5% between 2020 and 2025, and the pandemic accelerated a shift already underway. Patients and payers alike wanted therapy delivered outside hospitals from 2020 onward, and infusion suites that closed never fully reopened at prior capacity. The United States benefit introduced in 2021 was funded below what providers needed, which limited how much demand converted into device volume.
Base case growth of 8.8% rests on three mechanisms. Biologic therapy volumes keep expanding across oncology, immunology and rare disease, and an increasing proportion of those regimens is being moved deliberately out of hospital settings. Elastomeric pumps take share from electronic devices wherever training burden and alarm fatigue matter more than programmability. And vascular access volumes grow with every long-course antimicrobial, parenteral nutrition and chemotherapy regimen delivered outside a hospital ward.
The bull case at 10.0% assumes European and Asian payers build home infusion reimbursement pathways comparable to the United States, which would enlarge the addressable base considerably. The bear case at 7.6% turns on subcutaneous conversion moving faster than expected: if the major intravenous biologics convert to on-body or prefilled subcutaneous administration within five years, pump and catheter volumes fall rather than grow.

Home Infusion Devices: Payer Arithmetic and Access Risk

Everything here follows from one comparison. The same antibiotic course, immunoglobulin infusion or chemotherapy regimen costs a payer roughly 62% less delivered at home than in a hospital outpatient suite, and the device is a trivial fraction of either figure. That gap funds the whole category, and it explains why device selection follows what a provider can operate rather than what performs best.

TOP FIVE CONCENTRATION51%Established infusion manufacturers hold most disposable consumable revenue

CONSUMABLE REVENUE SHARE79%Sets, cassettes and access devices rather than durable pumps

SITE OF CARE SAVING62%Cost reduction moving an infusion from hospital to home

ADMINISTRATION SET PRICEUSD 14.50Blended global price per single-use infusion administration set

CATHETER DWELL DURATION28 daysTypical time a peripherally inserted central catheter remains placed

SUBCUTANEOUS CONVERSION RATE23%Intravenous biologic regimens now available in subcutaneous form

The revenue sits in disposables, not hardware. Pumps are frequently placed with providers at minimal cost and generate 21% of revenue; administration sets, cassettes, connectors and catheters supply the rest across the years a patient remains on therapy. That model is unusually exposed here, because the pump is not always necessary. Elastomeric devices deliver a fixed volume at a fixed rate with no electronics at all.

The threat comes from pharmaceutical formulation rather than from device competition. Roughly 23% of intravenous biologic regimens now have a subcutaneous equivalent, and hyaluronidase-enabled large-volume subcutaneous injection keeps extending that list. Each conversion removes an infusion pump, a vascular access device, an administration set and often a nursing visit simultaneously. On-body injectors capture part of that value, but the total device content falls sharply.

"Home infusion device companies spend their time competing with each other and their real competition is a formulation scientist adding hyaluronidase to an intravenous biologic. When that works, the whole delivery chain disappears in a single regulatory approval."
Director, Infusion Systems and Home Care Technology Practice · MMA Medical Devic

Market Trends

Subcutaneous conversion removes intravenous delivery chains entirely

Hyaluronidase-enabled formulations now permit large-volume subcutaneous administration of biologics that previously required intravenous infusion, and approvals have accelerated sharply across oncology and immunology since 2024. Roughly 23% of intravenous biologic regimens have a subcutaneous equivalent available today. Each conversion removes a pump, a vascular access device, an administration set and frequently a nursing visit at the same time. On-body wearable injectors capture part of the displaced value at 13.2% growth, but total device content per patient falls rather than rises through the transition. No device company holds any influence over those formulation decisions or advance visibility into them.

Market Impact: Reduces payer cost by 62%

Elastomeric simplicity wins where training and alarms fail

Elastomeric pumps are a balloon in a shell delivering a fixed volume at a fixed rate, with no battery, no screen and no alarm. They grow at 10.4% because home settings punish complexity: a patient or family member operating an electronic pump generates support calls, alarm fatigue and programming errors that a disposable device simply cannot produce. Providers running large patient panels have shifted antibiotic and chemotherapy protocols toward elastomerics deliberately. Margin per unit is lower and consumption is entirely predictable, which suits provider purchasing better than pump placement does.

Market Impact: Over 500 sets per patient

Market Opportunities and Growth Drivers

Payer site-of-care policies push infusions out of hospitals

United States commercial payers have written explicit site-of-care policies requiring that eligible infusions be delivered at home or in a physician office rather than a hospital outpatient department, because the same therapy costs roughly 62% less outside the hospital. European payers have begun applying similar logic through tariff design rather than through explicit policy. This is administrative rather than clinical, and it moves patient volume faster than any clinical evidence has ever managed to. Device demand follows those policy decisions almost directly. Device demand follows those policy decisions almost mechanically.

Market Impact: Infection ends 100% of programmes

Biologic and rare disease volumes expand long-duration therapy

Immunoglobulin replacement, enzyme replacement, biologic immunology therapy and long-course antimicrobial regimens all involve repeat administration over months or years rather than a single course. Those are exactly the therapies that suit home delivery, and their volumes keep growing as rare disease diagnosis improves and biologic pipelines mature. A patient on weekly immunoglobulin for a decade consumes several hundred administration sets and multiple vascular access placements, which is a different commercial proposition from an acute hospital admission. Commercial attention in this market should follow therapy duration rather than patient count, and it frequently does the opposite.

Market Impact: Covers only 1 nurse-visit day

Market Restraints and Challenges

Catheter bloodstream infection risk gates programme expansion

A central line in a home environment carries infection risk that a hospital ward can monitor and a living room cannot, and a cluster of catheter-related bloodstream infections will close a home infusion programme regardless of its cost savings. The root cause is that aseptic technique depends on the patient or a family member rather than trained staff. Commercial impact is a hard ceiling on which therapies payers will authorise at home. Manufacturers respond with antimicrobial catheter coatings, disinfecting connector caps and simplified access protocols that reduce technique dependence. Home outcome evidence carries far more weight than hospital data here.

Market Impact: Roughly 23% of regimens converted

United States home infusion reimbursement remains persistently underfunded

The Medicare home infusion therapy benefit introduced in 2021 pays only for days when a nurse is physically present, which excludes most of the pharmacy, supply and monitoring cost a provider actually incurs. The root cause is a statutory definition written narrowly during legislative drafting. Commercial impact has been direct: relatively few suppliers enrolled and Medicare patients often remain in hospital outpatient settings that cost the programme more. Provider associations continue pressing for legislative correction, and several state Medicaid programmes have built better-designed alternatives. Legislative correction has been sought since the benefit first took effect.

Market Impact: Elastomeric growth reaching 10.4%

3 additional market trends, 4 additional growth drivers, and 2 additional restraints and challenges are covered in the full report. Contact sales@marketmindsadvisory.com to access the complete intelligence.

Segment CAGR and Growth Architecture

Segmentation follows device type, because device type determines the regulatory pathway, the clinical training requirement, the purchasing centre and the consumable stream that follows placement. Six device types cover home and ambulatory parenteral delivery without overlap. Therapy indication cuts across every device type and is treated as an application attribute here. Device type sets the commercial rules.

home-infusion-therapy-devices-market-market-share-analysis-1787303476655

On-Body Wearable Injectors

Growing at 13.2%, a full 1.50x the market rate, on-body injectors deliver large-volume subcutaneous doses over minutes to hours from a device adhered to the abdomen or thigh, with no vascular access and usually no clinician present. They exist because pharmaceutical companies wanted their intravenous biologics deliverable at home without an infusion chain, and hyaluronidase-enabled formulations made the volumes achievable. Device selection is made by the drug manufacturer during formulation development rather than by any provider or payer, which is a completely different commercial relationship from the rest of this market. Combination product regulation applies throughout. Supply is effectively locked once a regulatory filing names the device, which is why this segment carries the strongest margins in the market.

CAGR 13.2%

Elastomeric Disposable Infusion Pumps

Elastomeric pumps grow at 10.4% by being deliberately unsophisticated. A pressurised balloon inside a protective shell delivers a fixed volume at a fixed flow rate determined by tubing bore, with no battery, screen, alarm or programming step to go wrong in a patient's home. Home infusion providers running large panels have moved outpatient antibiotic and continuous chemotherapy protocols toward them, because support calls and programming errors cost more than the device does. Unit margin runs below electronic pumps, and consumption is entirely predictable, which suits provider purchasing behaviour considerably better than capital placement arrangements. Flow rate is fixed by tubing bore at manufacture, so nothing about the therapy can be adjusted once the device leaves the pharmacy.

CAGR 10.4%

Full segment breakdown across 6 segments available in the complete report.

Regional Architecture and Country Demand Map

Regional value tracks reimbursement design more than clinical practice or population, because home infusion only happens where a payer has decided to fund it. The United States built that architecture first and most completely, and every other region is at an earlier stage of the same construction.

North America

North America leads at 32%, and the reason is a reimbursement architecture no other health system has built. United States commercial payers apply explicit site-of-care policies pushing eligible infusions out of hospital outpatient departments, and a national home infusion provider network including Option Care Health and Optum Infusion exists to receive that volume. Nothing comparable operates elsewhere. Medicare's own benefit remains narrowly drafted and underfunded, which holds public volume below its potential. Canadian provinces fund community infusion through regional health authorities at lower unit prices. Growth at 8.0% is moderate because the conversion from hospital settings is already well advanced here. Site-of-care policy rather than clinical evidence continues to set the pace of conversion here.

Share: 32% | CAGR: 8.0% (2026 to 2036)

Western Europe

Twenty-four per cent of value, growing at 7.4%. National systems fund home parenteral therapy through hospital budgets rather than through separate benefits, which means the hospital decides whether to send a patient home and captures the saving directly. That produces good adoption in immunoglobulin replacement and home parenteral nutrition, where the United Kingdom, Netherlands and Nordic countries run mature programmes. It produces much weaker adoption in oncology, where day-unit capacity is already funded and there is little incentive to move it. Germany and France buy devices through hospital tenders at prices well below United States levels. Whoever captures the saving decides whether the patient goes home, and in this region that is the hospital itself rather than any separate payer.

Share: 24% | CAGR: 7.4% (2026 to 2036)

Regional intelligence for 5 additional markets available in the complete report: East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe. Contact sales@marketmindsadvisory.com.

home-infusion-therapy-devices-market-country-cagr-analysis-1787303477178

Where Home Infusion Value Actually Sits

Devices are a small fraction of what home infusion costs and a large fraction of whether it works safely, so the commercial contest turns on provider operability, infection outcomes and pharmaceutical relationships rather than on price or specification. Nothing durable in this market is won on the pump itself. The pump itself decides very little.

Win the pharmaceutical formulation decision before clinical development ends

On-body injector selection is made by the drug manufacturer during formulation development, years before any provider or payer is involved, and it locks device supply for the product's commercial life. That is a business development relationship rather than a medical device sale. Combination product programmes typically run 4 years from device selection to approval, so the commercial window opens and closes long before the market sees the therapy. Device companies organised around hospital and provider selling consistently miss it, because nobody in that organisation is talking to formulation scientists. Nobody in a device sales organisation is talking to those people.

Market Impact: Locks device supply across 4 full d

Design for provider operations rather than clinical specification

Home infusion providers select devices on support call volume, training time and error rate, not on programmability or feature depth. An electronic pump generating frequent alarm calls costs a provider more in nursing time than the device saves, which is precisely why elastomerics grow at 10.4% against better-specified competitors. Manufacturers who measure their products by provider operating cost rather than clinical capability build far more durable positions. It requires accepting that the least sophisticated product in a portfolio may be the one that should be promoted hardest. Support call volume is the number that actually decides these accounts.

Market Impact: The elastomeric segment is now grow

Compete on infection outcomes because programmes close without them

A cluster of catheter-related bloodstream infections closes a home programme regardless of what it saves, so infection performance is the only clinical variable that genuinely changes purchasing behaviour. Antimicrobial catheter coatings, disinfecting connector caps and simplified access protocols reduce technique dependence in settings where the operator is a family member. Suppliers who fund outcome studies in home rather than hospital populations hold roughly 30% more provider accounts, because the hospital evidence base does not transfer credibly to a living room. Hospital infection evidence does not transfer credibly into a living room.

Market Impact: Holds around 30% more active provid

Build vascular access annuity around long-duration therapy patients

A patient on weekly immunoglobulin or long-course parenteral nutrition consumes over 500 administration sets and several vascular access placements across a treatment lifetime, which dwarfs the value of any single pump. Manufacturers holding both access devices and consumables for those therapies capture the whole stream rather than one part. Commercial attention should follow therapy duration rather than patient count. Short-course antimicrobial patients are numerous and generate a fraction of the lifetime value that far fewer chronic therapy patients produce over a decade. Short-course antimicrobial patients are numerous and individually worth very little across a decade.

Market Impact: Exceeds 500 sets across a single pa

Who Controls the Margin Pool

Concentration sits at 51% across the top five, measured on annual revenue from infusion devices and consumables supplied into home and ambulatory settings, the single basis applied throughout. Baxter International and ICU Medical lead, followed by B. Braun, Becton Dickinson and Fresenius Kabi. All five built their positions in hospital infusion and extended outward, so they sell through clinical specification and tender rather than the provider operations lens home settings reward.

Competition runs on three dimensions. Provider operability comes first, covering support call volume, training burden and error rate, which is why simple disposable devices outgrow sophisticated ones. Infection performance comes second and is the only clinical variable that reliably shifts purchasing, since a bloodstream infection cluster ends a programme. Pharmaceutical relationship comes third and applies only to on-body injectors, where the drug manufacturer chooses the device during formulation development.

Pressure arrives from an unfamiliar direction. Pharmaceutical formulation teams converting intravenous biologics to subcutaneous administration remove infusion device content entirely, and no device company has any influence over those decisions. Separately, Chinese and Indian consumable manufacturers supply domestic home care markets at prices international suppliers cannot match. Rankings shift most where a device company builds genuine drug delivery partnership capability.

home-infusion-therapy-devices-market-company-positioning-matrix-1787303477702

Competitive Moat and Risk Dimensions

BAXTER INTERNATIONAL

Moat: Breadth across therapy and consumable

Baxter supplies pumps, administration sets, parenteral nutrition solutions and access consumables into the same patient episode, which lets it contract with home infusion providers across a whole therapy rather than a single item. That breadth makes tender comparison difficult and it gives the company a purchasing relationship competitors selling individual devices cannot easily replicate or displace.

BAXTER INTERNATIONAL

Risk: Hospital-centred commercial model

The organisation is built around hospital clinical specification and tender selling, which is a poor match for home providers who buy on support call volume and training time. Subcutaneous conversion removes device content from precisely the biologic therapies Baxter serves. Its position in combination product device supply is thinner than its scale in infusion would suggest.

ICU MEDICAL

Moat: Connector and access installed position

Needleless connectors and vascular access consumables carry protocol lock-in that is unusually strong, because changing connector type means retraining every nurse and patient in a provider network and revalidating aseptic procedure. The infection evidence base attached to those products reinforces the position, since providers will not experiment with a component that sits directly in the bloodstream pathway.

ICU MEDICAL

Risk: Integration and portfolio complexity

The company absorbed a large infusion portfolio through acquisition and carries the platform overlap and service obligation that came with it, which constrains investment elsewhere. Emerging market consumable manufacturers compete hard on connector pricing. Any move by providers toward simplified single-supplier disposable sets would erode a component-level position built on specification rather than on system supply.

Players Tracked

Prominent Players

Baxter International

ICU Medical

B. Braun

Becton Dickinson

Fresenius Kabi

Other Key Players

Terumo Corporation

Nipro Corporation

Moog Inc.

Avanos Medical

Teleflex

Ypsomed

West Pharmaceutical Services

Enable Injections

Gerresheimer

Eitan Medical

Micrel Medical Devices

Zyno Medical

Vygon

Amsino International

Shandong Weigao Group

Recent Developments

APRIL 2025

Enable Injections expands on-body injector manufacturing for oncology partners

Enable Injections commissioned additional on-body injector production capacity to serve oncology combination product partners, an organic expansion rather than an acquisition, responding to subcutaneous conversion programmes that pharmaceutical companies had committed to several years earlier during formulation development. No acquisition or partner facility was involved.

Signal: Device volume in this category is now bein

SEPTEMBER 2025

United States provider associations press for home infusion benefit correction

Home infusion provider associations renewed legislative pressure to widen the Medicare home infusion therapy benefit beyond days when a nurse is physically present, a definition that has excluded most pharmacy, supply and monitoring costs since the benefit took effect in 2021. The benefit has been unchanged since then.

Signal: Public reimbursement design rather than cl

FEBRUARY 2026

Baxter extends elastomeric pump range for outpatient antimicrobial therapy

Baxter International broadened its elastomeric infusion pump range with additional fill volumes and flow rates aimed at outpatient parenteral antimicrobial therapy programmes, an organic product extension responding to provider preference for devices carrying no electronics, alarms or programming requirements. No electronics were added to any variant.

Signal: Providers keep choosing simplicity over ca

Polymer, Electronics and Sterilisation Cost Exposure

Cost structures here are dominated by medical-grade polymer and by sterilisation rather than by anything electronic. Medical-grade PVC, polyurethane and polycarbonate account for roughly 31% of administration set and catheter cost of goods, with resin sourced from a small set of qualified suppliers because material change control is expensive. Ethylene oxide sterilisation and validated packaging contribute a further 17%, and precision extrusion of catheter tubing carries most of the remainder.

Ethylene oxide capacity constraint through 2022 and 2023 showed the exposure most clearly. United States facility closures under Environmental Protection Agency emissions scrutiny removed contract sterilisation capacity from an already tight market, and Becton Dickinson and Baxter both disclosed sterilisation availability and cost pressure in their annual reporting for those years. Manufacturers could not reprice into provider contracts written annually, so margin absorbed most of the increase across the industry.

The disadvantage falls hardest on manufacturers relying on contract sterilisation without owned capacity. A company holding its own ethylene oxide or radiation sterilisation runs its schedule; a company buying capacity queues behind larger customers when supply tightens. Geography compounds it: Western producers face emissions regulation and energy costs that Chinese and Indian manufacturers do not.

home-infusion-therapy-devices-market-cost-volatility-analysis-1787303477897

Secure owned or dedicated sterilisation capacity rather than contracting it

Contract sterilisation is allocated to whoever holds the largest standing commitment, and home infusion consumables rarely outrank hospital volumes when capacity tightens. Owning ethylene oxide or radiation capability costs considerably more per unit in normal conditions and it converts a supply interruption into a scheduling question rather than a stockout that loses provider contracts permanently.

Qualify alternative medical-grade resin grades across the consumable portfolio

Material change control makes single-product resin requalification expensive, so the economics only work when an alternative grade is qualified once across many product codes at the same time. Manufacturers carrying broad consumable families spread that cost thinly enough to hold two approved resin sources permanently, which removes the worst of the supply and pricing exposure.

Write provider supply agreements with narrow resin and sterilisation indexation

Annual provider contracts written at fixed pricing transferred the whole polymer and sterilisation increase onto manufacturers during the last cycle. Newer agreements increasingly carry narrow indexation covering named resin grades and sterilisation cost only. Providers accept that more readily than a general escalator, because the underlying benchmarks are external, published and clearly outside any single supplier's control.

Portfolio Architecture for Margin Defence

Margin architecture divides by how much protocol or regulatory work a change requires. Standard administration sets and basic tubing compete on delivered price, since providers switch without retraining anybody. Vascular access devices and needleless connectors earn considerably more, because changing them means retraining a nursing network and revalidating aseptic procedure. On-body injectors earn the most, protected by combination product regulation and by a supply agreement written into a dru

The volume versus premium tension sits between provider-selected and manufacturer-selected products. Providers buy on operating cost and switch readily, which caps pricing across most of the consumable range. Pharmaceutical companies select on-body injectors during formulation development and cannot practically change afterwards, which supports pricing that no provider negotiation would ever permit. Those are two different businesses that happen to share a factory and very little else.

High-value pools concentrate where switching carries clinical or regulatory consequence. Antimicrobial-coated catheters, disinfecting connector caps and closed system transfer components all sit directly in the infection pathway, where providers will not experiment. Combination product device supply sits behind a regulatory filing that names the device. Plain administration sets and generic elastomeric pumps sit at the other extreme entirely, tendered annually on delivered price alone.

Volume / Commodity-Adjacent Tier

Standard administration sets, extension lines, basic elastomeric pumps and general infusion consumables, where providers switch freely on delivered price and Chinese and Indian manufacturers set the cost floor across most emerging market volume.

Gross Margin: 26-38%

Premium / Certified Tier

Vascular access devices, needleless connectors and ambulatory electronic pumps, protected by nursing protocol lock-in, aseptic procedure revalidation and the infection evidence base attached to components sitting in the bloodstream pathway.

Gross Margin: 48-62%

Sustainability / Regulatory / Next-Generation Tier

On-body wearable injectors and combination product delivery systems, protected by regulatory filings naming the device and by supply agreements written during drug development. Best margins available and the least contestable position in the market.

Gross Margin: 60-74%

home-infusion-therapy-devices-market-portfolio-architecture-1787303478405

Consumable Streams Across Therapy Duration

Value here follows how long a patient stays on therapy rather than how many patients start it. A short antimicrobial course consumes a handful of sets and one peripheral access placement. A patient on weekly immunoglobulin replacement or home parenteral nutrition consumes over 500 administration sets, several vascular access placements and years of connector and dressing supply. Commercial attention should follow duration, and it frequently follows patient count instead.

Stickiness varies sharply by component. Needleless connectors and vascular access devices are the stickiest, because changing them requires retraining an entire nursing network and revalidating aseptic protocol, and providers will not risk that for a price difference. Electronic pumps sit in the middle, held by training investment and provider familiarity. Plain sets and extension lines show no stickiness and change supplier at every renewal.

Buyer profiles have consolidated considerably. A decade ago individual home infusion agencies and hospital discharge teams made device decisions locally. Today national provider networks and group purchasing arrangements contract centrally, and for on-body injectors the decision has moved outside healthcare entirely to pharmaceutical formulation teams. Suppliers organised around clinical selling now find the decision-maker is a procurement director or a drug programme manager.

home-infusion-therapy-devices-market-end-use-penetration-index-1787303478893

Where Infusion Device Strategy Lands

These are among the four positions where our research anticipates prominent divergence between winners and laggards over the coming forecast period. Each is grounded in the demand model, the regulatory perimeter, and the announced capacity pipeline.

01 / FORMULATION PARTNERSHIP CAPABILITY

The on-body decision happens years before any market exists

Pharmaceutical companies select their on-body injector suppliers during formulation development, typically a full four years before approval, and combination product regulation then locks that supply across the product's entire commercial life. It is a business development relationship rather than a medical device sale, conducted with formulation scientists rather than with clinicians, providers or procurement officers. Device companies organised entirely around hospital and provider selling consistently miss those windows, simply because nobody anywhere in the organisation is having the relevant conversation.

02 / PROVIDER OPERABILITY DESIGN

Home settings reward simplicity over clinical capability every time

Home infusion providers select devices on support call volume, training time and error rate rather than on programmability, which is why elastomeric pumps carrying no electronics grow at 10.4% against far better-specified electronic competitors. An electronic pump generating frequent alarm calls costs a provider more in nursing hours than the device itself will ever save them. Manufacturers should be measuring their products by provider operating cost, even where that means promoting the least sophisticated item in the whole portfolio hardest.

03 / INFECTION OUTCOME EVIDENCE

One bloodstream infection cluster closes an entire programme

Catheter-related bloodstream infection is the only clinical variable that reliably changes purchasing behaviour here, because a cluster of them will close a home programme whatever cost savings it was delivering to the payer. Aseptic technique in a living room depends on a patient or family member rather than trained ward staff, so technique-independent design matters far more than it does in hospitals. Suppliers who fund infection outcome studies in home rather than hospital populations hold roughly 30% more provider accounts than those relying on ward evidence.

04 / CONVERSION EXPOSURE MAPPING

Subcutaneous reformulation removes the whole delivery chain at once

Roughly 23% of intravenous biologic regimens already have a subcutaneous equivalent available, and each conversion removes a pump, a vascular access device, an administration set and frequently a nursing visit in one regulatory approval. No device company holds any influence over those pharmaceutical formulation decisions, nor any advance visibility into when they will land. Manufacturers should be mapping exactly which of their revenue sits behind biologics carrying active subcutaneous programmes, because that particular exposure stays entirely invisible in most portfolio reviews.

Engagement Snapshot From the Field

A live engagement with an industry participant carrying material or product regulatory and market exposure ahead of a defining policy shift, showing how our research translates into a defensible multi-year portfolio strategy.

MARKET MINDS ADVISORY · CLIENT ENGAGEMENT SUMMARY

Home Infusion Therapy Devices Producer Strategic Portfolio Review and Transition Roadmap 2026·Investment Scenario on Home Infusion Therapy Devices Exposure Evaluation 2025-26

CLIENT PROFILE

A European infusion consumables manufacturer supplying administration sets, extension lines and elastomeric pumps into hospital and home care channels across Western Europe and Latin America, with annual revenue of approximately USD 340 million (client-reported, unverified by MMA). Roughly 70% came from standard consumables sold through annual tenders. The company held no vascular access portfolio and no combination product or on-body injector capability at all.

STRATEGIC CHALLENGE

Standard consumable pricing had eroded for five consecutive years under Chinese and Indian competition while resin and sterilisation costs rose, and hospital tender volumes were flat. The board wanted to know whether to defend consumable share through manufacturing cost reduction, acquire a vascular access portfolio carrying protocol lock-in, or attempt to enter combination product device supply where margins looked considerably better.

MMA APPROACH

MMA conducted 47 expert interviews across home infusion provider operations directors, hospital discharge planners, infusion nurses, pharmaceutical formulation leads and contract sterilisation operators in six countries. A quantitative survey of 3,800 respondents established device selection authority, switching behaviour and support burden by setting. We then modelled contribution margin and share trajectory for all three options against observed tender erosion and subcutaneous conversion timetables.

KEY FINDINGS

Home infusion provider operations directors ranked support call volume and training time above every clinical specification when selecting devices, and none cited programmability as a selection factor at all.
Needleless connector and vascular access switching required retraining an entire nursing network and revalidating aseptic protocol, and no provider surveyed had changed connector supplier in the previous four years.
Pharmaceutical formulation leads selected on-body injector partners roughly four years before approval and regarded the relationship as effectively unchangeable once regulatory filings named the device.
Standard administration set tender pricing had eroded consistently and procurement officers expected the pattern to continue, with none anticipating reversal on quality or supply reliability grounds.

CLIENT PROFILE

STRATEGIC CHALLENGE

MMA APPROACH

KEY FINDINGS

Home infusion provider operations directors ranked support call volume and training time above every clinical specification when selecting devices, and none cited programmability as a selection factor at all.
Needleless connector and vascular access switching required retraining an entire nursing network and revalidating aseptic protocol, and no provider surveyed had changed connector supplier in the previous four years.
Pharmaceutical formulation leads selected on-body injector partners roughly four years before approval and regarded the relationship as effectively unchangeable once regulatory filings named the device.
Standard administration set tender pricing had eroded consistently and procurement officers expected the pattern to continue, with none anticipating reversal on quality or supply reliability grounds.

RECOMMENDED STRATEGY

Phase 1: Phase one: treat standard consumables as cash generation and cut manufacturing cost rather than investing further, accepting continued share and price decline there. Phase 2: Phase two: acquire a vascular access and connector portfolio carrying established infection evidence, since protocol lock-in there resists the price competition eroding sets. Phase 3: Phase three: defer combination product entry until the access acquisition is integrated, given the four-year formulation relationship cycle and the business development capability required.

OUTCOME

The client acquired a mid-sized vascular access and connector business for approximately USD 175 million (client-reported, unverified by MMA) and reduced standard consumable manufacturing cost by roughly a fifth. Eighteen months on, blended gross margin had improved about seven percentage points, and connector revenue had proved considerably more stable through the tender cycle than sets.

Frequently Asked Questions

Foundational context covering the market sizes, CAGR, scope, country, region and competition that inform every finding below. This section is provided to cover basics and most often pre-purchase conversations, answered from the MMA Primary Research Dataset.

What is the current size of the Home Infusion Therapy Devices Market?

The global home infusion therapy devices market was valued at USD 6.8 billion in 2025, covering ambulatory and elastomeric pumps, vascular access devices, administration sets and on-body injectors. Home infusion nursing and pharmacy services fall outside this definition.

How large will the Home Infusion Therapy Devices Market be by 2036?

MMA forecasts the market at USD 17.2 billion by 2036, expanding 2.32 times from the 2026 base of USD 7.4 billion. That represents roughly USD 9.8 billion of incremental value across the forecast decade.

What is the CAGR for the Home Infusion Therapy Devices Market 2026 to 2036?

The base case compound annual growth rate is 8.8%, with a bull case of 10.0% and a bear case of 7.6%. The bear case reflects faster subcutaneous conversion removing infusion device content entirely.

Which segment is growing fastest?

On-body wearable injectors grow at 13.2%, a full 1.50x the overall market rate. They are selected by pharmaceutical companies during formulation development rather than by providers or payers.

Who are the major companies in the Home Infusion Therapy Devices Market?

Baxter International, ICU Medical, B. Braun, Becton Dickinson and Fresenius Kabi together hold 51% of revenue, all five having built their positions in hospital infusion and then extended them outward into home settings.

Which country is growing fastest?

India grows fastest at 12.8%, driven by private home healthcare networks and families paying out of pocket to avoid extended hospital stays. South Asia and Pacific is the fastest region at 11.0%.

Report Segmentation Architecture

The full report scope spans multiple orthogonal segmentation dimensions, with cross-tabulated demand data provided for each dimension pair. Coverage extends further to regional breakdowns, trend trajectories, and the competitive detail needed to support segment-level decision-making.

By Device Type

Ambulatory Electronic Infusion Pumps
Elastomeric Disposable Infusion Pumps
Syringe Infusion Pumps
Vascular Access Devices
Infusion Administration Sets and Connectors
On-Body Wearable Injectors

By End-Use Industry

Home Infusion Provider Networks
Hospital Discharge and Outreach Programmes
Ambulatory Infusion Suites
Specialty Pharmacy Operations
Long-Term Care and Residential Facilities
Pharmaceutical Combination Product Programmes

By Commercial Dimension

Home Infusion Provider Contracts
Group Purchasing Organisation Agreements
Hospital and National Tender Supply
Specialty Pharmacy Distribution
Pharmaceutical Device Supply Agreements
Direct and Out-of-Pocket Patient Sales

By Region

North America
Western Europe
East Asia
South Asia and Pacific
Latin America
Middle East and Africa
Eastern Europe

Scope, Methodology, and Coverage

Every figure in this report is reproducible from documented input assumptions. The scope below maps the historical period, the forecast horizon, the segmentation dimensions, and the countries covered, alongside the underlying primary and qualitative methodology.

Historical Period

2020 to 2025

Forecast Period

2026 to 2036

Base Year

2025 (USD billions; MMA Primary Research Dataset, August 2026)

Market Definition

This market comprises devices and single-use consumables used to deliver parenteral therapy in home and ambulatory settings, measured at manufacturer revenue across provider contracts, purchasing organisation agreements, specialty pharmacy distribution and pharmaceutical device supply arrangements. Coverage spans ambulatory electronic infusion pumps and their cassettes, elastomeric disposable infusion pumps, syringe infusion pumps, vascular access devices including peripherally inserted central catheters, midlines and implanted ports, infusion administration sets, extension lines and needleless connectors, and on-body wearable injectors supplied as part of combination products. Hospital bedside and critical care infusion pumps, home infusion nursing and compounding pharmacy services, the infused drugs and nutrition solutions themselves, enteral feeding pumps and sets, peritoneal and haemodialysis equipment, insulin pumps, and patient-controlled analgesia devices used within hospitals fall outside scope.

Quantitative Units

USD billions (current prices); consumable unit volumes by device type; installed ambulatory pump base; average price per administration set; treated patient episodes by therapy duration

Segmentation Dimensions

By Device Type; By End-Use Industry; By Commercial Dimension; By Region

Regions Covered

North America, Western Europe, East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe

Countries Covered

United States, Canada, Mexico, Germany, France, United Kingdom, Italy, Spain, Netherlands, Sweden, Denmark, Japan, China, South Korea, Taiwan, India, Australia, Singapore, Malaysia, Thailand, Brazil, Argentina, Chile, Colombia, Saudi Arabia, United Arab Emirates, Israel, South Africa, Poland, Czechia, Hungary, Romania, and additional markets relevant to home parenteral therapy analysis

Key Companies Profiled

Baxter International, ICU Medical, B. Braun, Becton Dickinson, Fresenius Kabi, Terumo Corporation, Nipro Corporation, Moog Inc., Avanos Medical, Teleflex, Ypsomed, West Pharmaceutical Services, Enable Injections, Gerresheimer, Eitan Medical, Micrel Medical Devices, Zyno Medical, Vygon, Amsino International, Shandong Weigao Group

Quantitative Methodology

Primary survey, n=3,800 respondents, Q4 2025, six countries; demand-side model with trade association cross-validation

Qualitative Methodology

47 expert interviews, Q4 2025; applied to validate demand model assumptions, identify emerging dynamics, and assess competitive positioning

Report Format

PDF and XLSX data workbook (Word format preview document)

Publisher

Market Minds Advisory

Report Code

MMA-2026-MED-108

Published

August 2026

Contact

sales@marketmindsadvisory.com | www.marketmindsadvisory.com

Purchase the full Home Infusion Therapy Devices Market Report (2026 to 2036).

The full MMA report treats home infusion as the reimbursement construct it actually is, quantifying site-of-care economics by therapy and mapping where device content survives the shift to subcutaneous administration. It sizes six device types and seven regions to 2036, modelling consumable volumes, therapy duration and pump placement separately so lifetime patient value can be distinguished from patient count. Competitive assessment covers twenty manufacturers on one consistent revenue basis. Input cost exposure is traced through medical-grade resin sourcing and sterilisation capacity constraint. Four commercial levers and a strategic verdict close the report, grounded in 47 expert interviews and a 3,800-respondent survey.

Six device types sized separately to 2036

Subcutaneous conversion exposure mapped by therapy class

Provider operability drivers quantified across device selection

Twenty manufacturers assessed on one consistent basis

Therapy duration modelled against lifetime consumable value

Anonymised client engagement with tested strategic recommendations

Built For The People Who Decide

From boardroom strategy to bench-side execution, this report is read cover-to-cover by leaders shaping the next decade of their industry, turning demand scenarios, market dynamics and valuation benchmarks into decisions.

CXOs/ Presidents/ VPs/ Managers

M&A and Corporate Development

Strategy Teams and R&D Heads

Procurement and Product Directors

Regulatory and Compliance Leaders

Investor Relations and Equity Analysts